Clinical Trial Update: Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating Exablate Blood-Brain Barrier disruption for recurrent glioblastoma in patients receiving carboplatin monotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: InSightec | Conditions: Recurrent Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED